Loading...
•
Mar 31, 2020
Eton Q1 2020 Earnings Report
Eton reported first quarter results, facing challenges from COVID-19 but maintaining a strong financial position.
Key Takeaways
Eton Pharmaceuticals reported first quarter results with revenue of $0.1 million, impacted by the COVID-19 pandemic, and a net loss of $9.0 million. The company acquired marketing rights to Alkindi Sprinkle and strengthened its balance sheet with $9.8 million of additional liquidity.
Launched Biorphen in December 2019, but commercial launch was negatively impacted by COVID-19.
Acquired marketing rights to orphan drug Alkindi Sprinkle.
Increased digital promotional activities to offset in-person marketing restrictions.
Working on a vial presentation of Biorphen expected to launch in 2021.
Forward Guidance
Eton anticipates multiple additional product launches later in the year and does not anticipate material disruption to its research and development or regulatory timelines due to COVID-19.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...